BIOTECH ASSISTANT / FIELD NOTES

BioAgilytix opens a 360biolabs laboratory in Sydney

Company / institutional announcement · BioAgilytix

Source published: · Event / reporting date: 2026-10-26

Site published: 2026-11-04 · Updated: 2026-11-04

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

What changed

BioAgilytix announced a new 360biolabs laboratory in Sydney's Macquarie Park district. The company describes support for time-sensitive clinical samples, PBMC isolation, flow cytometry, and sample storage. It says shared procedures and quality systems support assay transfer across its laboratory network. These are company-reported capabilities.

Why it may matter

Potential business relevance: track disclosed capabilities or development plans; independent validation and project-specific applicability still require review.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Bioanalysis & Biomarkers

Related updates

Labcorp

Labcorp poster evaluates orthogonal RNA and DNA integrity checks for CGT bioanalysis

Labcorp published a conference-poster summary on independent RNA and DNA integrity assessment in cell and gene therapy bioanalysis. It evaluates Agilent TapeStation microfluidic electrophoresis as an orthogonal quality-control tool alongside qPCR and RT-qPCR, which do not directly measure overall integrity. The public summary describes the evaluation's objective and rationale, without quantitative performance results or peer-reviewed publication metadata.

Bioanalysis / PubMed

Review explains statistical pitfalls in anti-drug antibody assay cut points

Based on the PubMed abstract, this review explains how sample selection, experimental balance, outlier handling, transformation, and statistical methods affect anti-drug antibody assay cut points. It addresses screening, confirmation, titers, drug tolerance, and reassessment using clinical baseline samples. This is a practical review of validation decisions, not a new clinical efficacy study.

Bioanalysis / PubMed

Review examines greener solvent systems for bioanalytical microextraction

Based on the PubMed abstract, a Bioanalysis review examines switchable-hydrophilicity solvents and bio-derived deep eutectic solvents for sample preparation. It discusses extraction performance, matrix effects, reproducibility, and environmental trade-offs, with future emphasis on miniaturization and automation. The review evaluates methodological opportunities rather than validating a specific assay for regulated clinical sample analysis.

Continue your research

Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.

Open free member tools ↗
AI assistant ↗